ePrints

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)

Lookup NU author(s): Professor Alan Calvert

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods:Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma. The drug was given as a bolus infusion at a 4-weekly dose of 150 mu g/m(2). A total of 140 patients were entered and a total of 285 courses were administered. Results: In general, the compound was well tolerated. Myelotoxicity was the most common toxicity. Grade 3 and 4 leukopenia was observed in 18.6% of the courses, neutropenia in 20.3%, thrombocytopenia in 16.2% and anemia in 8.7%. Double nadirs were seen in a total of 41 courses for neutrophils, in 40 for leukocytes and in 3 for platelets. Non-hematological toxicity was very mild. Only one partial response in a patient with melanoma was seen. Conclusions: At this dose and schedule carzelesin did not yield activity in the types of turners studied.

Publication metadata

Author(s): Pavlidis, N., Aamdal, S., Awada, A., Calvert, A. H., Fumoleau, P., Sorio, R., Punt, C., Verweij, J., van Oosterom, A., Morant, R., Wanders, J., Hanauske, A. R.

Publication type: Article

Publication status: Published

Journal: Cancer Chemotherapy and Pharmocology

Year: 2000

Volume: 46

Issue: 2

Pages: 167-171

ISSN (print): 0344-5704

ISSN (electronic): 1432-0843

URL: http://dx.doi.org/10.1007/s002800000134

DOI: 10.1007/s002800000134

Altmetrics

Share